天康生物(002100.SZ):2020年度將申請總額不超52億元的銀行貸款
格隆匯4月10日丨天康生物(002100.SZ)公佈,公司第七屆董事會第三次會議召開,審議並通過公司《2020年度關於向商業銀行申請借款授信總額的議案》;
為保證公司2020年度正常經營資金需求,根據公司2020年度生產經營計劃及飼料業務、製藥業務、植物蛋白業務、生豬養殖業務、玉米收儲業務的發展需要,有效降低公司經營過程中由於原材料價格波動所帶來的經營風險,保證原材料的穩定供應,增加製藥業務的全國市場佔有率,擴大養殖業務規模,充分發揮植物蛋白業務的產能,為飼料企業提供優質蛋白原料,以提高各板塊的盈利能力,2020年度公司將申請總額不超過52億元(包括借新還舊)的銀行貸款。
該議案須提交公司2020年第一次臨時股東大會審議。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.